Strong Cash Position , Progress being made
Interim Updates ......
PTX-100 expands study on promising results in T-cell lymphoma patients
Patients with T-cell lymphomas (TCL) are being steadily enrolled and treated in the expansion cohort under the leadership of Professor Miles Prince, AM.
Prescient anticipates that recruitment remains on track for completion by the end of calendar 2022 and looks forward to sharing an interim update as the trial unfolds....NZT
Ann: June 2022 Quarterly Update and Appendix 4C, page-4
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
